Bohemine
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407146

CAS#: 189232-42-6

Description: Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 µM. Bohemine is structurally similar to Olomoucine and Roscovitine.


Price and Availability

Size Price Shipping out time Quantity
100mg USD 850 2 Weeks
200mg USD 1650 2 Weeks
500mg USD 2250 2 Weeks
1g USD 3450 2 Weeks
2g USD 4850 2 Weeks
5g USD 7650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-27. Prices are subject to change without notice.

Bohemine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 407146
Name: Bohemine
CAS#: 189232-42-6
Chemical Formula: C18H24N6O
Exact Mass: 340.20116
Molecular Weight: 340.43
Elemental Analysis: C, 63.51; H, 7.11; N, 24.69; O, 4.70


Synonym: Bohemine

IUPAC/Chemical Name: 3-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol

InChi Key: OPQGFIAVPSXOBO-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H24N6O/c1-13(2)24-12-21-15-16(20-11-14-7-4-3-5-8-14)22-18(23-17(15)24)19-9-6-10-25/h3-5,7-8,12-13,25H,6,9-11H2,1-2H3,(H2,19,20,22,23)

SMILES Code: CC(N1C=NC2=C1N=C(NCCCO)N=C2NCC3=CC=CC=C3)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Novakova O, Liskova B, Vystrcilova J, Suchankova T, Vrana O, Starha P, Travnicek Z, Brabec V. Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine. Eur J Med Chem. 2014 May 6;78:54-64. doi: 10.1016/j.ejmech.2014.03.041. Epub 2014 Mar 15. PubMed PMID: 24675180.

2: Liskova B, Zerzankova L, Novakova O, Kostrhunova H, Travnicek Z, Brabec V. Cellular response to antitumor cis-Dichlorido platinum(II) complexes of CDK inhibitor Bohemine and its analogues. Chem Res Toxicol. 2012 Feb 20;25(2):500-9. doi: 10.1021/tx200525n. Epub 2012 Feb 1. PubMed PMID: 22250642.

3: Franek F, Strnad M, Havlícek L, Siglerová V, Fismolová I, Eckschlager T. Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma culture. Cytotechnology. 2001 Jul;36(1-3):117-23. doi: 10.1023/A:1014020415912. PubMed PMID: 19003322; PubMed Central PMCID: PMC3449669.

4: Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res. 2005 Jul 1;11(13):4875-87. PubMed PMID: 16000586.

5: Trávnícek Z, Malon M, Zatloukal M, Dolezal K, Strnad M, Marek J. Mixed ligand complexes of platinum(II) and palladium(II) with cytokinin-derived compounds Bohemine and Olomoucine: X-ray structure of [Pt(BohH+-N7)Cl(3)].9/5H2O [Boh=6-(benzylamino)-2-[(3-(hydroxypropyl)-amino]-9-isopropylpurine, Bohemine]. J Inorg Biochem. 2003 Apr 1;94(4):307-16. PubMed PMID: 12667701.

6: Kovarova H, Halada P, Man P, Dzubak P, Hajduch M. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Technol Cancer Res Treat. 2002 Aug;1(4):247-56. PubMed PMID: 12625783.

7: Rypka M, Veselý J, Chmela Z, Riegrová D, Cervenková K, Havlícek L, Lemr K, Hanus J, Cerný B, Lukes J, Michalíková K. In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes. Xenobiotica. 2002 Nov;32(11):1017-31. PubMed PMID: 12487731.

8: Kovárová H, Hajdúch M, Korínková G, Halada P, Krupicková S, Gouldsworthy A, Zhelev N, Strnad M. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Electrophoresis. 2000 Nov;21(17):3757-64. PubMed PMID: 11271495.

9: Chmela Z, Veselý J, Lemr K, Rypka M, Hanus J, Havlícek L, Krystof V, Michnová L, Fuksová K, Lukes J. In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route. Drug Metab Dispos. 2001 Mar;29(3):326-34. PubMed PMID: 11181503.